The company successfully priced a $33.1 million equity offering at $72.00 per share with participation from reputable institutional investors (Great Point Partners, Surveyor Capital, Squadron Capital, etc.), demonstrating investor confidence. The capital raise provides substantial funding for advancing their lead Phase 3 candidate SGT-610, which has orphan and breakthrough designations, supporting near-term clinical development and commercialization activities.
Also mentions SLGL
Articles that tag SLGL but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
